{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T21:50:07Z","timestamp":1790027407578,"version":"4.0.1"},"reference-count":62,"publisher":"American Association for Cancer Research (AACR)","issue":"4","funder":[{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["1KL2TR001444"],"award-info":[{"award-number":["1KL2TR001444"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["1R01DE028563"],"award-info":[{"award-number":["1R01DE028563"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["1U01DE028227"],"award-info":[{"award-number":["1U01DE028227"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"CCSG","award":["P30CA23100"],"award-info":[{"award-number":["P30CA23100"]}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,2,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>There is a critical need to understand mechanisms of resistance and to develop combinatorial strategies to improve responses to checkpoint blockade immunotherapy (CBI). Here, we uncover a novel mechanism by which the human papillomavirus (HPV) inhibits the activity of CBI in head and neck squamous cell carcinoma (HNSCC). Using orthotopic HNSCC models, we show that radiation combined with anti\u2013PD-L1 immunotherapy significantly enhanced local control, CD8+ memory T cells, and induced preferential T-cell homing via modulation of vascular endothelial cells. However, the HPV E5 oncoprotein suppressed immune responses by downregulating expression of major histocompatibility complex and interfering with antigen presentation in murine models and patient tumors. Furthermore, tumors expressing HPV E5 were rendered entirely resistant to anti\u2013PD-L1 immunotherapy, and patients with high expression of HPV16 E5 had worse survival. The antiviral E5 inhibitor rimantadine demonstrated remarkable single-agent antitumor activity. This is the first report that describes HPV E5 as a mediator of resistance to anti\u2013PD-1\/PD-L1 immunotherapy and demonstrates the antitumor activity of rimantadine. These results have broad clinical relevance beyond HNSCC to other HPV-associated malignancies and reveal a powerful mechanism of HPV-mediated immunosuppression, which can be exploited to improve response rates to checkpoint blockade.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>This study identifies a novel mechanism of resistance to anti\u2013PD-1\/PD-L1 immunotherapy mediated by HPV E5, which can be exploited using the HPV E5 inhibitor rimantadine to improve outcomes for head and neck cancer patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/0008-5472.can-19-1771","type":"journal-article","created":{"date-parts":[[2019,12,17]],"date-time":"2019-12-17T15:29:10Z","timestamp":1576596550000},"page":"732-746","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":64,"title":["HPV16 E5 Mediates Resistance to PD-L1 Blockade and Can Be Targeted with Rimantadine in Head and Neck Cancer"],"prefix":"10.1158","volume":"80","author":[{"given":"Sayuri","family":"Miyauchi","sequence":"first","affiliation":[{"name":"1Department of Radiation Medicine and Applied Sciences, University of California, San Diego, La Jolla, California."},{"name":"2Moores Cancer Center, University of California, San Diego, La Jolla, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. Dominick","family":"Sanders","sequence":"additional","affiliation":[{"name":"1Department of Radiation Medicine and Applied Sciences, University of California, San Diego, La Jolla, California."},{"name":"2Moores Cancer Center, University of California, San Diego, La Jolla, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kripa","family":"Guram","sequence":"additional","affiliation":[{"name":"1Department of Radiation Medicine and Applied Sciences, University of California, San Diego, La Jolla, California."},{"name":"2Moores Cancer Center, University of California, San Diego, La Jolla, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sangwoo S.","family":"Kim","sequence":"additional","affiliation":[{"name":"1Department of Radiation Medicine and Applied Sciences, University of California, San Diego, La Jolla, California."},{"name":"2Moores Cancer Center, University of California, San Diego, La Jolla, California."},{"name":"3School of Medicine, University of California, San Diego, La Jolla, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Paolini","sequence":"additional","affiliation":[{"name":"4HPV-Unit, UOSD Tumor Immunology and Immunotherapy, IRCCS Regina Elena National Cancer Institute, Rome, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2322-6857","authenticated-orcid":false,"given":"Aldo","family":"Venuti","sequence":"additional","affiliation":[{"name":"4HPV-Unit, UOSD Tumor Immunology and Immunotherapy, IRCCS Regina Elena National Cancer Institute, Rome, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ezra E.W.","family":"Cohen","sequence":"additional","affiliation":[{"name":"2Moores Cancer Center, University of California, San Diego, La Jolla, California."},{"name":"5Department of Medicine, Division of Hematology-Oncology, University of California, San Diego, La Jolla, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Silvio","family":"Gutkind","sequence":"additional","affiliation":[{"name":"2Moores Cancer Center, University of California, San Diego, La Jolla, California."},{"name":"6Department of Pharmacology, University of California, San Diego, La Jolla, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph A.","family":"Califano","sequence":"additional","affiliation":[{"name":"2Moores Cancer Center, University of California, San Diego, La Jolla, California."},{"name":"7Department of Surgery, Division of Otolaryngology, University of California, San Diego, La Jolla, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew B.","family":"Sharabi","sequence":"additional","affiliation":[{"name":"1Department of Radiation Medicine and Applied Sciences, University of California, San Diego, La Jolla, California."},{"name":"2Moores Cancer Center, University of California, San Diego, La Jolla, California."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2020,2,14]]},"reference":[{"key":"2022061706335368800_bib1","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1056\/NEJMoa1602252","article-title":"Nivolumab for recurrent squamous-cell carcinoma of the head and neck","volume":"375","author":"Ferris","year":"2016","journal-title":"N Engl J Med"},{"key":"2022061706335368800_bib2","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/S1470-2045(16)30066-3","article-title":"Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial","volume":"17","author":"Seiwert","year":"2016","journal-title":"Lancet Oncol"},{"key":"2022061706335368800_bib3","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/S0140-6736(18)31999-8","article-title":"Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study","volume":"393","author":"Cohen","year":"2019","journal-title":"Lancet"},{"key":"2022061706335368800_bib4","doi-asserted-by":"crossref","first-page":"e498","DOI":"10.1016\/S1470-2045(15)00007-8","article-title":"Radiation and checkpoint blockade immunotherapy: radiosensitisation and potential mechanisms of synergy","volume":"16","author":"Sharabi","year":"2015","journal-title":"Lancet Oncol"},{"key":"2022061706335368800_bib5","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1158\/2326-6066.CIR-14-0196","article-title":"Stereotactic radiation therapy augments antigen-specific PD-1-mediated antitumor immune responses via cross-presentation of tumor antigen","volume":"3","author":"Sharabi","year":"2015","journal-title":"Cancer Immunol Res"},{"key":"2022061706335368800_bib6","doi-asserted-by":"crossref","first-page":"435","DOI":"10.3389\/fonc.2018.00435","article-title":"Radiation therapy combined with checkpoint blockade immunotherapy for metastatic undifferentiated pleomorphic sarcoma of the maxillary sinus with a complete response","volume":"8","author":"Guram","year":"2018","journal-title":"Front Oncol"},{"key":"2022061706335368800_bib7","doi-asserted-by":"crossref","first-page":"4211","DOI":"10.1158\/1078-0432.CCR-18-0871","article-title":"Immune modulation of head and neck squamous cell carcinoma and the tumor microenvironment by conventional therapeutics","volume":"25","author":"Miyauchi","year":"2019","journal-title":"Clin Cancer Res"},{"key":"2022061706335368800_bib8","doi-asserted-by":"crossref","first-page":"687","DOI":"10.2217\/fon-2018-0405","article-title":"JAVELIN head and neck 100: a phase III trial of avelumab and chemoradiation for locally advanced head and neck cancer","volume":"15","author":"Yu","year":"2019","journal-title":"Future Oncol"},{"key":"2022061706335368800_bib9","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/s12885-019-5266-4","article-title":"Phase I\/II trial of durvalumab plus tremelimumab and stereotactic body radiotherapy for metastatic head and neck carcinoma","volume":"19","author":"Bahig","year":"2019","journal-title":"BMC Cancer"},{"key":"2022061706335368800_bib10","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.ctro.2018.01.005","article-title":"Anti PD-L1 DUrvalumab combined with cetuximab and RadiOtherapy in locally advanced squamous cell carcinoma of the head and neck: A phase I\/II study (DUCRO)","volume":"9","author":"Bonomo","year":"2018","journal-title":"Clin Transl Radiat Oncol"},{"key":"2022061706335368800_bib11","doi-asserted-by":"crossref","first-page":"TPS6097","DOI":"10.1200\/JCO.2017.35.15_suppl.TPS6097","article-title":"A randomized phase II study of chemoradiation (CRT) \u00b1 nivolumab (Nivo) with sequential safety evaluations of Nivo \u00b1 lirilumab (Liri) or ipilumumab (Ipi) concomitant with (C) RT in intermediate (IR) and high-risk (HR) head and neck squamous cell carcinoma (HNSCC) (RTOG 3504, NCT02764593)","volume":"35","author":"Gillison","year":"2017","journal-title":"J Clin Oncol"},{"key":"2022061706335368800_bib12","doi-asserted-by":"crossref","first-page":"CT163","DOI":"10.1158\/1538-7445.AM2018-CT163","article-title":"Abstract CT163: KEYNOTE-412: pembrolizumab plus chemoradiation vs. chemoradiation alone for locally advanced head and neck squamous cell carcinoma","volume":"78","author":"Siu","year":"2018","journal-title":"Cancer Res"},{"key":"2022061706335368800_bib13","doi-asserted-by":"crossref","first-page":"6011","DOI":"10.1200\/JCO.2017.35.15_suppl.6011","article-title":"Safety of pembrolizumab with chemoradiation (CRT) in locally advanced squamous cell carcinoma of the head and neck (LA-SCCHN)","volume":"35","author":"Powell","year":"2017","journal-title":"J Clin Oncol"},{"key":"2022061706335368800_bib14","doi-asserted-by":"crossref","first-page":"e1356153","DOI":"10.1080\/2162402X.2017.1356153","article-title":"Ionizing radiation sensitizes tumors to PD-L1 immune checkpoint blockade in orthotopic murine head and neck squamous cell carcinoma","volume":"6","author":"Oweida","year":"2017","journal-title":"Oncoimmunology"},{"key":"2022061706335368800_bib15","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1177\/0022034509333446","article-title":"Replication and assembly of human papillomaviruses","volume":"88","author":"Conway","year":"2009","journal-title":"J Dent Res"},{"key":"2022061706335368800_bib16","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.tim.2017.07.007","article-title":"The HPV E6\/E7 oncogenes: key factors for viral carcinogenesis and therapeutic targets","volume":"26","author":"Hoppe-Seyler","year":"2018","journal-title":"Trends Microbiol"},{"key":"2022061706335368800_bib17","doi-asserted-by":"crossref","first-page":"e17","DOI":"10.4081\/oncol.2012.e17","article-title":"Mechanisms of virus immune evasion lead to development from chronic inflammation to cancer formation associated with human papillomavirus infection","volume":"6","author":"Senba","year":"2012","journal-title":"Oncol Rev"},{"key":"2022061706335368800_bib18","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/S0168-1702(02)00123-5","article-title":"Evasion of host immunity directed by papillomavirus-encoded proteins","volume":"88","author":"O'Brien","year":"2002","journal-title":"Virus Res"},{"key":"2022061706335368800_bib19","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1186\/1476-4598-10-140","article-title":"Papillomavirus E5: the smallest oncoprotein with many functions","volume":"10","author":"Venuti","year":"2011","journal-title":"Mol Cancer"},{"key":"2022061706335368800_bib20","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.virol.2010.07.044","article-title":"HPV-16 E5 down-regulates expression of surface HLA class I and reduces recognition by CD8 T cells","volume":"407","author":"Campo","year":"2010","journal-title":"Virology"},{"key":"2022061706335368800_bib21","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1002\/ijc.25004","article-title":"All 4 di-leucine motifs in the first hydrophobic domain of the E5 oncoprotein of human papillomavirus type 16 are essential for surface MHC class I downregulation activity and E5 endomembrane localization","volume":"126","author":"Cortese","year":"2010","journal-title":"Int J Cancer"},{"key":"2022061706335368800_bib22","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1002\/ijc.20558","article-title":"E5 protein of human papillomavirus type 16 selectively downregulates surface HLA class I","volume":"113","author":"Ashrafi","year":"2005","journal-title":"Int J Cancer"},{"key":"2022061706335368800_bib23","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.virol.2013.05.006","article-title":"The E5 proteins","volume":"445","author":"DiMaio","year":"2013","journal-title":"Virology"},{"key":"2022061706335368800_bib24","doi-asserted-by":"crossref","first-page":"534","DOI":"10.4161\/hv.23232","article-title":"Immunotherapy in new pre-clinical models of HPV-associated oral cancers","volume":"9","author":"Paolini","year":"2013","journal-title":"Hum Vaccin Immunother"},{"key":"2022061706335368800_bib25","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1001\/archotol.133.5.495","article-title":"The role of human papillomavirus 16 E6 in anchorage-independent and invasive growth of mouse tonsil epithelium","volume":"133","author":"Hoover","year":"2007","journal-title":"Arch Otolaryngol Head Neck Surg"},{"key":"2022061706335368800_bib26","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1177\/0194599812442037","article-title":"Comparative analysis of tumor-infiltrating lymphocytes in a syngeneic mouse model of oral cancer","volume":"147","author":"Judd","year":"2012","journal-title":"Otolaryngol Head Neck Surg"},{"key":"2022061706335368800_bib27","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-019-13471-0","article-title":"Syngeneic animal model of tobacco-associated oral cancer reveals the activity of in situ anti-CTLA-4","author":"Wang","year":"2019","journal-title":"Nat Commun"},{"key":"2022061706335368800_bib28","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1002\/ijc.30081","article-title":"Characterization of functionally active gene fusions in human papillomavirus related oropharyngeal squamous cell carcinoma","volume":"139","author":"Guo","year":"2016","journal-title":"Int J Cancer"},{"key":"2022061706335368800_bib29","doi-asserted-by":"crossref","first-page":"7168","DOI":"10.1158\/0008-5472.CAN-14-2458","article-title":"Trafficking of T cells into tumors","volume":"74","author":"Slaney","year":"2014","journal-title":"Cancer Res"},{"key":"2022061706335368800_bib30","doi-asserted-by":"crossref","first-page":"44418","DOI":"10.18632\/oncotarget.17901","article-title":"Characterization of tumor-associated T-lymphocyte subsets and immune checkpoint molecules in head and neck squamous cell carcinoma","volume":"8","author":"Lechner","year":"2017","journal-title":"Oncotarget"},{"key":"2022061706335368800_bib31","doi-asserted-by":"crossref","first-page":"e965570","DOI":"10.4161\/21624011.2014.965570","article-title":"Distinct patterns of intratumoral immune cell infiltrates in patients with HPV-associated compared to non-virally induced head and neck squamous cell carcinoma","volume":"4","author":"Partlova","year":"2015","journal-title":"Oncoimmunology"},{"key":"2022061706335368800_bib32","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.cell.2017.01.017","article-title":"Primary, adaptive, and acquired resistance to cancer immunotherapy","volume":"168","author":"Sharma","year":"2017","journal-title":"Cell"},{"key":"2022061706335368800_bib33","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1002\/ijc.29373","article-title":"HPV16 E5 expression induces switching from FGFR2b to FGFR2c and epithelial-mesenchymal transition","volume":"137","author":"Ranieri","year":"2015","journal-title":"Int J Cancer"},{"key":"2022061706335368800_bib34","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1159\/000494985","article-title":"From HPV infection to lesion progression: the role of HLA alleles and host immunity","volume":"63","author":"Paaso","year":"2019","journal-title":"Acta Cytol"},{"key":"2022061706335368800_bib35","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.antiviral.2018.08.005","article-title":"Alkyl-imino sugars inhibit the pro-oncogenic ion channel function of human papillomavirus (HPV) E5","volume":"158","author":"Wetherill","year":"2018","journal-title":"Antiviral Res"},{"key":"2022061706335368800_bib36","doi-asserted-by":"crossref","first-page":"5341","DOI":"10.1128\/JVI.06243-11","article-title":"High-risk human papillomavirus E5 oncoprotein displays channel-forming activity sensitive to small-molecule inhibitors","volume":"86","author":"Wetherill","year":"2012","journal-title":"J Virol"},{"key":"2022061706335368800_bib37","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1001\/archoto.2009.159","article-title":"Immune response during therapy with cisplatin or radiation for human papillomavirus-related head and neck cancer","volume":"135","author":"Spanos","year":"2009","journal-title":"Arch Otolaryngol Head Neck Surg"},{"key":"2022061706335368800_bib38","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1002\/hed.21040","article-title":"Preclinical models of HPV+ and HPV- HNSCC in mice: an immune clearance of HPV+ HNSCC","volume":"31","author":"Williams","year":"2009","journal-title":"Head Neck"},{"key":"2022061706335368800_bib39","doi-asserted-by":"crossref","first-page":"7985","DOI":"10.1158\/0008-5472.CAN-04-1525","article-title":"Sublethal irradiation of human tumor cells modulates phenotype resulting in enhanced killing by cytotoxic T lymphocytes","volume":"64","author":"Garnett","year":"2004","journal-title":"Cancer Res"},{"key":"2022061706335368800_bib40","doi-asserted-by":"crossref","first-page":"7516","DOI":"10.4049\/jimmunol.174.12.7516","article-title":"Local radiation therapy of B16 melanoma tumors increases the generation of tumor antigen-specific effector cells that traffic to the tumor","volume":"174","author":"Lugade","year":"2005","journal-title":"J Immunol"},{"key":"2022061706335368800_bib41","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1084\/jem.20052494","article-title":"Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy","volume":"203","author":"Reits","year":"2006","journal-title":"J Exp Med"},{"key":"2022061706335368800_bib42","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.ijrobp.2003.09.012","article-title":"Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated","volume":"58","author":"Demaria","year":"2004","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2022061706335368800_bib43","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1038\/s41591-018-0232-2","article-title":"Radiotherapy induces responses of lung cancer to CTLA-4 blockade","volume":"24","author":"Formenti","year":"2018","journal-title":"Nat Med"},{"key":"2022061706335368800_bib44","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/nature14292","article-title":"Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer","volume":"520","author":"Twyman-Saint Victor","year":"2015","journal-title":"Nature"},{"key":"2022061706335368800_bib45","doi-asserted-by":"crossref","first-page":"e0157164","DOI":"10.1371\/journal.pone.0157164","article-title":"Optimizing timing of immunotherapy improves control of tumors by hypofractionated radiation therapy","volume":"11","author":"Young","year":"2016","journal-title":"PLoS One"},{"key":"2022061706335368800_bib46","doi-asserted-by":"crossref","first-page":"3727","DOI":"10.1158\/1078-0432.CCR-14-2824","article-title":"Ablative tumor radiation can change the tumor immune cell microenvironment to induce durable complete remissions","volume":"21","author":"Filatenkov","year":"2015","journal-title":"Clin Cancer Res"},{"key":"2022061706335368800_bib47","doi-asserted-by":"crossref","first-page":"5458","DOI":"10.1158\/0008-5472.CAN-14-1258","article-title":"Acquired resistance to fractionated radiotherapy can be overcome by concurrent PD-L1 blockade","volume":"74","author":"Dovedi","year":"2014","journal-title":"Cancer Res"},{"key":"2022061706335368800_bib48","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1016\/j.ijrobp.2009.10.014","article-title":"Selective changes in the immune profile of tumor-draining lymph nodes after different neoadjuvant chemoradiation regimens for locally advanced cervical cancer","volume":"76","author":"Battaglia","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2022061706335368800_bib49","doi-asserted-by":"crossref","first-page":"12468","DOI":"10.18632\/oncotarget.3487","article-title":"Targeting the inhibitory receptor CTLA-4 on T cells increased abscopal effects in murine mesothelioma model","volume":"6","author":"Wu","year":"2015","journal-title":"Oncotarget"},{"key":"2022061706335368800_bib50","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1158\/2326-6066.CIR-17-0040","article-title":"Stereotactic radiotherapy increases functionally suppressive regulatory T cells in the tumor microenvironment","volume":"5","author":"Muroyama","year":"2017","journal-title":"Cancer Immunol Res"},{"key":"2022061706335368800_bib51","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.pvr.2017.08.002","article-title":"Modulation of antigen presenting cell functions during chronic HPV infection","volume":"4","author":"Bashaw","year":"2017","journal-title":"Papillomavirus Res"},{"key":"2022061706335368800_bib52","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1002\/ijc.22089","article-title":"E5 protein of human papillomavirus 16 downregulates HLA class I and interacts with the heavy chain via its first hydrophobic domain","volume":"119","author":"Ashrafi","year":"2006","journal-title":"Int J Cancer"},{"key":"2022061706335368800_bib53","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.virusres.2006.02.005","article-title":"Down-regulation of MHC class I is a property common to papillomavirus E5 proteins","volume":"120","author":"Ashrafi","year":"2006","journal-title":"Virus Res"},{"key":"2022061706335368800_bib54","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/S0042-6822(03)00103-X","article-title":"The E5 protein of human papillomavirus type 16 perturbs MHC class II antigen maturation in human foreskin keratinocytes treated with interferon-gamma","volume":"310","author":"Zhang","year":"2003","journal-title":"Virology"},{"key":"2022061706335368800_bib55","doi-asserted-by":"crossref","first-page":"3185","DOI":"10.1128\/jvi.69.5.3185-3192.1995","article-title":"The E5 oncoprotein of human papillomavirus type 16 inhibits the acidification of endosomes in human keratinocytes","volume":"69","author":"Straight","year":"1995","journal-title":"J Virol"},{"key":"2022061706335368800_bib56","doi-asserted-by":"crossref","DOI":"10.3390\/v9090252","article-title":"Analysis of class I major histocompatibility complex gene transcription in human tumors caused by human papillomavirus infection","volume":"9","author":"Gameiro","year":"2017","journal-title":"Viruses"},{"key":"2022061706335368800_bib57","doi-asserted-by":"crossref","first-page":"4521","DOI":"10.1128\/jvi.67.8.4521-4532.1993","article-title":"The E5 oncoprotein of human papillomavirus type 16 transforms fibroblasts and effects the downregulation of the epidermal growth factor receptor in keratinocytes","volume":"67","author":"Straight","year":"1993","journal-title":"J Virol"},{"key":"2022061706335368800_bib58","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1006\/excr.1998.4024","article-title":"The human papillomavirus type 16 E5-protein modulates ligand-dependent activation of the EGF receptor family in the human epithelial cell line HaCaT","volume":"241","author":"Crusius","year":"1998","journal-title":"Exp Cell Res"},{"key":"2022061706335368800_bib59","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1078\/0171-9335-00060","article-title":"Modulation of the epidermal growth factor receptor by the human papillomavirus type 16 E5 protein in raft cultures of human keratinocytes","volume":"79","author":"Tomakidi","year":"2000","journal-title":"Eur J Cell Biol"},{"key":"2022061706335368800_bib60","doi-asserted-by":"crossref","first-page":"8051","DOI":"10.1128\/jvi.69.12.8051-8056.1995","article-title":"Effect of human papillomavirus type 16 oncogenes on MAP kinase activity","volume":"69","author":"Gu","year":"1995","journal-title":"J Virol"},{"key":"2022061706335368800_bib61","doi-asserted-by":"crossref","first-page":"103581","DOI":"10.18632\/oncotarget.21658","article-title":"Human papillomavirus type 18 E5 oncogene supports cell cycle progression and impairs epithelial differentiation by modulating growth factor receptor signalling during the virus life cycle","volume":"8","author":"Wasson","year":"2017","journal-title":"Oncotarget"},{"key":"2022061706335368800_bib62","doi-asserted-by":"crossref","first-page":"12162","DOI":"10.1128\/JVI.76.23.12162-12172.2002","article-title":"The human papillomavirus type 16 E5 protein impairs TRAIL- and FasL-mediated apoptosis in HaCaT cells by different mechanisms","volume":"76","author":"Kabsch","year":"2002","journal-title":"J Virol"}],"container-title":["Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/80\/4\/732\/2800551\/732.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/80\/4\/732\/2800551\/732.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,28]],"date-time":"2024-07-28T15:47:46Z","timestamp":1722181666000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerres\/article\/80\/4\/732\/646397\/HPV16-E5-Mediates-Resistance-to-PD-L1-Blockade-and"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,14]]},"references-count":62,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2020,2,14]]},"published-print":{"date-parts":[[2020,2,15]]}},"URL":"https:\/\/doi.org\/10.1158\/0008-5472.can-19-1771","relation":{"has-preprint":[{"id-type":"doi","id":"10.1158\/0008-5472.c.6511834.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.c.6511834","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22424644","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22424644.v1","asserted-by":"object"}]},"ISSN":["0008-5472","1538-7445"],"issn-type":[{"value":"0008-5472","type":"print"},{"value":"1538-7445","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,14]]}}}